Latest Breaking News On - Company phase iib - Page 1 : comparemela.com

Navidea Biopharmaceuticals, Inc Presses Ahead, Embraces Opportunities

Following the Company’s Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from.

United statesNavidea manoceptJill bieker stefanelliSimon alder blackburnDanaj mossJosh wilsonCardinal healthStrategic partnership initiativeSecurities exchangeFix fundCompany forwardCompany fixClinical researchCompany board of directorsNavidea biopharmaceuticals incCompany board

Navidea (NAVB) continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from NYSE

Navidea (NAVB) continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from NYSE
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJosh wilsonDanaj mossJill bieker stefanelliSimon alder blackburnCompany boardClinical researchKeystone capital partnersAmerican exchangeStrategic partnership initiativeMeilleur technologies incCompany fixNavidea biopharmaceuticals incFix fundCompany clinical site planCompany phase iib

Navidea Biopharmaceuticals, Inc Receives $7 5 Million Cash From Cardinal Health In Lieu Of Contingent Milestone Payment

Continuing the Company s Fix, Fund, Propel approach, the cash payment from Cardinal Health aligns strategic goals while solidifying immediate capita

United statesTheodore gerbickNavidea manoceptJason myersCompany phase iibCardinal healthCardinal health incNavidea biopharmaceuticals incSecurities exchangeNews globalNavidea biopharmaceuticalsAsset purchase agreementMilestone paymentKeystone capital partnersExecutive consultantsKeystone partners

Navidea Biopharmaceuticals, Inc Receives $7 5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

Continuing the Company’s Fix, Fund, Propel approach, the cash payment from Cardinal Health aligns strategic goals while solidifying immediate capital for funding Phase IIb and Phase III. | June 16, 2023

United statesNavidea manoceptJason myersNavidea biopharmaceuticals incCardinal healthCardinal health incSecurities exchangeCompany phase iibNavidea biopharmaceuticalsAsset purchase agreementMilestone paymentKeystone capital partnersExecutive consultantsKeystone partnersSecurities actSecurities exchange act

Navidea Biopharma (NAVB) to Sell Cardinal Milestone Payment for $8M, Enters New $2 75M Equity Line of Credit

Navidea Biopharma (NAVB) to Sell Cardinal Milestone Payment for $8M, Enters New $2 75M Equity Line of Credit
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTheodore gerbickJason myersJosh wilsonNavidea manoceptSecurities exchangeNavidea biopharmaceuticals incCompany phase iibCardinal milestone paymentEquity lineDirector joshSecurities actSecurities exchange actAnnual reportNavidea biopharmaceuticals